 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
MiMedx Group, Inc. (MDXG) develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare.
It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair.
The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing.
Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Shares are heading higher in an upward trading channel. The formation is supported by the stock's 50-day moving average shown in brown. Higher share prices are expected for this stock.
52-Weeks Trading Range: $6.94 - $17.47
Entry Point: $15.50
Stop Loss: $14.75
Target Price: $17.05
MDXG closed at $17.10
